Algal Oil Triglycerides Meta-analysis: What the Evidence Says

Algal Oil Triglycerides Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are m

3 min read · 595 wordsReviewed July 2026
A striking aerial image showcasing green algal blooms on a water surface in Dali, China. - Evidence evidence guide for algal oil triglycerides meta-analysis
Photo by Doing Be on Pexels · Pexels License

Quick Answer

Algal Oil Triglycerides Meta analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public health sources, so conclusions should be framed as evidence aware guidance rather than medical advice.

Key Takeaways

  • 01This page is generated only from sources stored in the Migaku evidence knowledge base.
  • 02Current evidence mix: 1 narrative review, 1 preclinical study.
  • 03Claims should be interpreted with the source type, study design, population, and publication date in mind.
  • 04This article is educational and does not replace care from a qualified clinician.

Algal Oil Triglycerides Meta-analysis: What the Evidence Says

Quick Answer

Algal Oil Triglycerides Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

  • This page is generated only from sources stored in the Migaku evidence knowledge base.
  • Current evidence mix: 1 narrative review, 1 preclinical study.
  • Claims should be interpreted with the source type, study design, population, and publication date in mind.
  • This article is educational and does not replace care from a qualified clinician.

Evidence Map

Source Evidence type Level Date Identifier
Fish oil supplements in patients with chronic kidney disease narrative review 3 2026-06-01 10.1093/ckj/sfag168
Microalgae Oil Attenuates Liver Fat Deposition in NAFLD via Modulation of Anti‐Lipogenic Genes and Insulin Signaling Pathways in HFD Mice preclinical study 4 2026-06-14 10.1002/fsn3.71882

What The Sources Report

  • 1 15 16 15 2 16 17 18 Most of the increased morbidity and mortality associated with CKD is attributable to CVD with an increased risk beginning with both mildly reduced estimated glomerular filtration rate (eGFR) and very low levels of albuminuria (albumin: creatinine ratio >30 mg/g). [Ferro Charles J (2026); evidence level 3]
  • This risk increases exponentially and independently with worsening eGFR and albuminuria with the highest risk being observed in individuals with severely reduced eGFR and high levels of albuminuria. [Ferro Charles J (2026); evidence level 3]
  • ALT AST DHA GO KEGG LDL-c MSEA NAFLD TBA TC TG 2022 2021 2023 2024 2026 2021 2015 2023 2021 2021 2009 2019 2014 2020 2026 2024 2025 n n n Non-alcoholic fatty liver disease (NAFLD), also known as metabolic dysfunction-associated steatotic liver disease (MASLD) in human pathology, is commonly associated with obesity. [AlQahtani Athba (2026); evidence level 4]
  • It is often linked to various health issues, including diabetes, hypertension, kidney diseases, and an increased risk of developing cardiovascular conditions. [AlQahtani Athba (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

For algal oil triglycerides meta-analysis, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

  • Ferro Charles J (2026). Fish oil supplements in patients with chronic kidney disease. DOI: 10.1093/ckj/sfag168. PMCID: PMC13261989. PMID: 42293365. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13261989/
  • AlQahtani Athba (2026). Microalgae Oil Attenuates Liver Fat Deposition in NAFLD via Modulation of Anti‐Lipogenic Genes and Insulin Signaling Pathways in HFD Mice. DOI: 10.1002/fsn3.71882. PMCID: PMC13265833. PMID: 42305223. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13265833/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.

FAQ

Frequently Asked Questions

M

Medically reviewed

Last reviewed July 30, 2026 by Migaku Evidence Review

← All GuidesSupplement Reference →